文献速递心力衰竭与心肌病

急性心力衰竭:当前药物治疗与展望

Acute heart failure: current pharmacological treatment and perspectives.
PubMed 文献 · Eur Heart J · 2023-01-01

该综述指出急性心力衰竭是65岁以上患者非计划入院最常见原因,症状多与全身静脉淤血相关。管理应以入院时减淤治疗为基础,出院前尽早启动指南指导的口服药物,并概述了ESC与ACC/AHA/HFSA的最新推荐及未来方向。

要点

  • 急性心衰初始管理以减淤治疗为主,出院前尽早启动指南指导的口服心衰药物。
  • 高血压诱发的急性心衰可考虑血管扩张剂作为初始治疗。
  • 急诊需进行风险分层,呼吸衰竭时使用无创通气。

核心结论

  • 急性心衰管理应基于减淤治疗,并在出院前快速启动指南指导的口服药物并结合密切随访。

研究设计与样本

  • 本为现状综述,基于近期大型随机临床试验和国际指南描述急性心衰当前药物治疗及未来研究方向。

主要发现

  • 急性心衰是65岁以上患者非计划入院最常见原因,症状多继发于全身静脉淤血。
  • 推荐药物治疗包括利尿治疗以缓解淤血并达到最佳液体状态,以及出院前尽早快速启动口服治疗。
  • 非药物治疗包括急诊风险分层和呼吸衰竭时的无创通气。
  • 高血压诱发的急性心衰应考虑血管扩张剂作为初始治疗。

关键数值与推荐

  • ESC和ACC/AHA/HFSA最新指南提供了急性心衰管理的更新推荐。
  • 推荐利尿治疗以缓解淤血并达到最佳液体状态。
  • 推荐出院前尽早快速启动口服治疗并结合密切随访。

临床怎么用

  • 入院即评估淤血并启动减淤治疗,出院前尽早启动指南指导的口服心衰药物。
  • 急诊进行风险分层,呼吸衰竭时使用无创通气。
  • 高血压诱发的急性心衰可考虑血管扩张剂作为初始治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute heart failure (AHF) represents the most frequent cause of unplanned hospital admission in patients older than 65 years. Symptoms and clinical signs of AHF (e.g. dyspnoea, orthopnoea, oedema, jugular vein distension, and variation of body weight) are mostly related to systemic venous congestion secondary to various mechanisms including extracellular fluids, increased ventricular filling pressures, and/or auto-transfusion of blood from the splanchnic into the pulmonary circulation. Thus, the initial management of AHF patients should be mostly based on decongestive therapies on admission followed, before discharge, by rapid implementation of guideline-directed oral medical therapies for heart failure. The therapeutic management of AHF requires the identification and rapid diagnosis of the disease, the diagnosis of the cause (or triggering factor), the evaluation of severity, the presence of comorbidities, and, finally, the initiation of a rapid treatment. The most recent guidelines from ESC and ACC/AHA/HFSA have provided updated recommendations on AHF management. Recommended pharmacological treatment for AHF includes diuretic therapy aiming to relieve congestion and achieve optimal fluid status, early and rapid initiation of oral therapies before discharge combined with a close follow-up. Non-pharmacological AHF management requires risk stratification in the emergency department and non-invasive ventilation in case of respiratory failure. Vasodilators should be considered as initial therapy in AHF precipitated by hypertension. On the background of recent large randomized clinical trials and international guidelines, this state-of-the-art review describes current pharmacological treatments and potential directions for future research in AHF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Deniau, Costanzo, Sliwa, et al. Acute heart failure: current pharmacological treatment and perspectives. Eur Heart J. 2023. PMID: 37850661. doi:10.1093/eurheartj/ehad617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。